These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11249827)

  • 1. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.
    Lister PD
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S33-8. PubMed ID: 11249827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
    Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.
    Lister PD; Sanders CC
    J Antimicrob Chemother; 2001 Jun; 47(6):811-8. PubMed ID: 11389113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA; Du X; Nicolau DP
    J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
    Zelenitsky SA; Ariano RE; Iacovides H; Sun S; Harding GK
    J Antimicrob Chemother; 2003 Apr; 51(4):905-11. PubMed ID: 12654762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
    Schafer J; Hovde LB; Simonson D; Rotschafer JC
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of moxifloxacin and levofloxacin simulating human serum and lung concentrations.
    Schubert S; Dalhoff A; Stass H; Ullmann U
    Infection; 2005 Dec; 33 Suppl 2():15-21. PubMed ID: 16518707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
    Huelves L; Sevillano D; Martínez-Marín C; López-Casla MT; Gracia M; Alou L; del Carmen Ponte M; Prieto J; Soriano F;
    Int J Antimicrob Agents; 2006 Apr; 27(4):294-9. PubMed ID: 16527462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model.
    Firsov AA; Vostrov SN; Lubenko IY; Arzamastsev AP; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2004 Jul; 54(1):178-86. PubMed ID: 15190041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae.
    Lemmen SW; Häfner H; Klik S; Lütticken R; Zolldann D
    Chemotherapy; 2003 May; 49(1-2):33-5. PubMed ID: 12714807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis].
    Soriano A; Jurado A; Marco F; Almela M; Ortega M; Mensa J
    Rev Esp Quimioter; 2005 Jun; 18(2):168-72. PubMed ID: 16130039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of fluoroquinolone kinetics of kill in susceptible and resistant gram-positive conjunctival pathogens.
    D'Arienzo PA; Wagner RS; Jamison T; Bell B; Dajcs JJ; Stroman DW
    Adv Ther; 2010 Jan; 27(1):39-47. PubMed ID: 20174904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae.
    Schentag JJ
    J Chemother; 2002 Feb; 14 Suppl 2():13-21. PubMed ID: 12003136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
    Lister PD
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bactericidal activity of moxifloxacin against multidrug-resistant Streptoccocus pneumoniae at clinically achievable serum and epithelial lining fluid concentrations compared with three other antimicrobials.
    Cafini F; Alou L; Sevillano D; Valero E; Prieto J;
    Int J Antimicrob Agents; 2004 Oct; 24(4):334-8. PubMed ID: 15380257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses.
    Firsov AA; Lubenko IY; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
    J Antimicrob Chemother; 2000 Nov; 46(5):725-32. PubMed ID: 11062191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of antibiotic effect and corneal epithelial toxicity of levofloxacin and moxifloxacin in vitro.
    Kim SY; Lim JA; Choi JS; Choi EC; Joo CK
    Cornea; 2007 Jul; 26(6):720-5. PubMed ID: 17592324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
    Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
    Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.